Related Experiment Video

Updated: Jul 11, 2025

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.9K

Chronic Active Antibody-mediated Rejection: Opportunity to Determine the Role of Interleukin-6 Blockade

Mel Berger1, Mary Baliker2, Teun Van Gelder3

  • 1Departments of Pediatrics and Pathology, Case Western Reserve University, Cleveland, OH.

Transplantation
|November 9, 2023
PubMed

Insights

Chronic active antibody-mediated rejection (caAMR) is a major cause of kidney transplant failure. The IMAGINE trial investigates clazakizumab, an interleukin-6 inhibitor, as a potential treatment for caAMR, offering hope for improved patient outcomes.

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation

Background:

  • Chronic active antibody-mediated rejection (caAMR) is the primary cause of late kidney allograft loss.
  • Current treatment options for AMR lack FDA approval and consensus, hindering effective patient care.
  • The development of new agents for transplantation has been slow, with no FDA approvals in over a decade.

Purpose of the Study:

  • To evaluate the efficacy of clazakizumab, an interleukin-6 (IL-6) inhibitor, in treating chronic active antibody-mediated rejection (caAMR).
  • To assess the potential of the IMAGINE trial to achieve accelerated FDA approval using a surrogate endpoint for kidney transplant rejection.

Main Methods:

  • The IMAGINE trial (NCT03744910) is a clinical study evaluating clazakizumab, a monoclonal antibody targeting IL-6.
  • The trial utilizes the slope of estimated glomerular filtration rate (eGFR) decline over one year as a surrogate endpoint for accelerated approval.
  • Enrollment in transplantation trials has historically been a challenge, impacting the development of new therapies.

Main Results:

  • Phase 2 studies of clazakizumab have demonstrated promising results in addressing AMR.
  • The IMAGINE trial is the first to be considered by the FDA for accelerated approval based on a surrogate endpoint for caAMR.

Conclusions:

  • Interleukin-6 (IL-6) is implicated as a key driver in the pathogenesis of AMR.
  • Clazakizumab represents a potential therapeutic advancement for patients suffering from caAMR.
  • This trial is a critical opportunity to improve the management of kidney transplant recipients with caAMR.

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

8.3K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

14.6K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
455
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
134
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
122